GSK
GSK proposes biopreparedness unit to combat global outbreaks
September 9, 2016Medical Communications, Research and Development Ebola, GSK, Zika
London-based pharma giant GlaxoSmithKline has proposed the creation of a biopreparedness unit to help avert crises like those we have …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
GSK, Roche and Novo back $86 million immuno-oncology startup
August 17, 2016Research and Development CD47, Cancer, GSK, Novo, Roche, Tioma, oncology
Brisbane-based venture-stage biopharmaceutical company Tioma Therapeutics has announced it has raised $86 million in Series A venture financing for its …
Apellis Pharmaceuticals appoints Dr Robert Kim as CMO
August 8, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment
Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
GSK and Alphabet to create bioelectronics medicines in £540 million partnership
August 1, 2016Research and Development, Sales and Marketing Alphabet, GSK, Verily, bioelectronic medicine, galvani, google
GlaxoSmithKline and Verily Life Sciences, a division of Google’s parent company Alphabet, have announced a £540 million partnership that will …
GSK announces significant post-Brexit UK investment
July 27, 2016Manufacturing and Production, Research and Development GSK, UK, brexit, investment
GlaxoSmithKline has given the UK life sciences industry a major boost in the post-Brexit landscape with an announcement that £275 …
GSK triple combo COPD therapy shows superiority in Phase III trials
June 20, 2016Research and Development, Sales and Marketing COPD, GSK, phase III
GlaxoSmithKline (LSE: GSK), along with Innoviva (NASDAQ: INVA), have presented positive top-line results from a pivotal Phase III trial for …
GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial
June 9, 2016Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab
GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …
GSK says asthma drug Breo shows superior results over standard care in major study
May 24, 2016Research and Development, Sales and Marketing COPD, GSK, asthma, breo, drug trial
UK drugmaker GlaxoSmithKline (LSE: GSK) on Tuesday said inhaled medicine Breo proved significantly better than standard care in a major …
China to cut prices of GSK, AstraZeneca drugs
May 23, 2016Sales and Marketing AstraZeneca, China, GSK, drug prices
Chinese health authorities have announced steps to cut the prices of three costly drugs in their latest attempt to reduce …
Novartis says trials show its COPD drug more effective versus GSK’s Seretide
May 16, 2016Research and Development, Sales and Marketing GSK, Novartis, drug trial, research
Swiss drug firm Novartis (VTX: NOVN) said its asthma drug showed efficacy over GlaxoSmithKline’s (LSE: GSK) medicine in a comparison …
Nice backs GSK’s lupus drug Benlysta
May 11, 2016Research and Development, Sales and Marketing GSK, NHS, NICE, regulation
The National Institute for Health and Care Excellence (Nice) has backed GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) to treat lupus. The …
In-depth: MSF takes on Pfizer, GSK
May 3, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Doctors Without Borders, GSK, Pfizer, analysis, medicins sans frontieres, patents, pneumonia
Medicins Sans Frontieres (MSF) recently stepped up their campaign to make the pneumonia vaccine more available in developing countries. Appearing …
GlaxoSmithKline Q1 earnings up 14% on new product sales
April 27, 2016Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Q1, earnings, results, revenue, sales
GlaxoSmithKline (LSE: GSK) reported a 14% rise in first-quarter earnings driven by demand for new drugs. The UK drug firm …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
